Glenmark Life Sciences Ltd.

Financial

	Glenmark Life Scienc	Neuland Laboratories	IOL Chem & Pharma
Operational Metrics
API Sector
US DMF Filings	520.0 .	66.0 .	n/a
Unclassified
Number of ANDA's Filed	n/a	n/a	n/a
R&D as a % of Total Sales	3.3 %	2.53 %	0.97 %
Financials
5 yr Average ROE	77.76 %	7.78 %	18.85 %
5yr average Equity Multiplier	5.38	1.65	1.4
5yr Average Asset Turnover Ratio	0.75	0.67	1.09
5yr Avg Net Profit Margin	20.48 %	6.73 %	12.19 %
Price to Book	4.36	8.54	1.46
P/E	21.58	30.51	13.51
5yr Avg Cash Conversion Cycle	87.84 Days	64.68 Days	55.45 Days
Inventory Days	90.19 Days	94.42 Days	57.94 Days
Days Receivable	124.34 Days	91.33 Days	80.26 Days
Days Payable	103.85 Days	114.5 Days	83.28 Days
5yr Average Interest Coverage Ratio	313.94	7.45	46.53
5yr Avg ROCE	95.75 %	11.07 %	24.63 %
5yr Avg Operating Profit Margin	30.33 %	15.88 %	18.65 %
5 yr average Debt to Equity	0.0	0.26	0.03
5yr CAGR Net Profit	19.01 %	58.32 %	-20.73 %
5yr Average Return on Assets	15.3 %	4.76 %	13.46 %
Shareholdings
Promoter Holding	82.85 %	32.74 %	48.19 %
Share Pledged by Promoters	9.47 %	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.01 %	-3.48 %	4.5 %
Change in Mutual Fund Holding (3 Yrs)	0.63 %	3.01 %	0.04 %

Business

	Glenmark Life Scienc	Neuland Laboratories	IOL Chem & Pharma
Product Wise Break-Up	Product Wise Break-Up Generic API 21.22 CDMO 1.55 API`s 0 Custom Manufacturing Solutions(CMS) 0 Generic Drug Substances(GDS) 0 API 0 Chemicals 0 Ethyl Acetate 0 Ibuprofen 0 Pantaprazole 0 Clopidogrel 0 Metformin 0 Others 77.23	Product Wise Break-Up Chemicals 0 API 0 Ethyl Acetate 0 Ibuprofen 0 Formulations 42.0 API`s 0 Pantaprazole 0 Metformin 0 CDMO 0 Custom Manufacturing Solutions(CMS) 55.0 Clopidogrel 0 Generic API 0 Others 3.0	Product Wise Break-Up Chemicals 40.0 API 21.0 Ethyl Acetate 0 Ibuprofen 39.0 Generic Drug Substances(GDS) 0 API`s 0 Pantaprazole 0 Metformin 0 CDMO 0 Custom Manufacturing Solutions(CMS) 0 Clopidogrel 0 Generic API 0
Location Wise Break-Up	Location Wise Break-Up India 52.43 Rest of the World 0 USA 0 Europe 0 Others 47.57	Location Wise Break-Up Europe 30.97 Rest of the World 12.48 USA 31.41 India 25.14	Location Wise Break-Up Europe 0 Rest of the World 30.94 USA 0 India 69.06
Customer Segment	Customer Segment Regulated Markets 83.0 Emerging Markets 17.0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up CVS 41.0 CNS 11.0 Pain Management 5.0 Diabetes 5.0 Anticonvulsant 0 Antidepressant 0 Antibacterial 0 Others 38.0	Therapeutic Area Break-Up Anti-bacterial 19.72 Anticonvulsant 10.46 CNS 0 Diabetes 0 Pain Management 0 Antidepressant 11.8 CVS 0 Others 58.02	-
Acute vs Chronic	Acute vs Chronic Chronic 62.0 Acute 38.0	-	-
Customer Wise Break-Up	Customer Wise Break-Up GPL 68.9 External 31.1	-	-
Asset Break-Up - Geography Wise	Asset Break-Up - Geography Wise Others 100	-	-

Glenmark Life Sciences Ltd.

Glenmark Life Sciences Ltd.

SIGN UP FOR FREE